Neoadjuvant Endocrine Therapy Versus Chemotherapy in Premenopausal Patients With ER+ & HER2- Breast Cancer

Abroad (travel likely)RecruitingPHASE3

Conditions

Breast Cancer

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Beijing Cancer Hospital Breast Center, Beijing, China

Study leads

Tao Ouyang, MD
Study Chair
Peking University Cancer Hospital & Institute

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)

Stage I Breast Cancer

Abroad (travel likely)RecruitingPHASE3

Birmingham, United States · Mobile, United States

Delayed Sentinel Lymph Node Biopsy in Ductal Cancer in Situ

DCIS · Breast Cancer · Breast Neoplasms

Abroad (travel likely)RecruitingPHASE3

Houston, United States · Hong Kong, Hong Kong

A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)

Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

IsraelRecruitingPHASE3

Daphne, United States · Auburn, United States

Culturally Adapting an Intervention to Increase Genetic Testing in African American Cancer Survivors

Female Breast Cancer · Prostate Cancer · Colorectal Carcinoma

Abroad (travel likely)Recruiting

Detroit, United States